source
- UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 yearsThe results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2…BioSpace · 22d ago↗ source
- AbbVie receives FDA approval for Parkinson’s drug Juvmo, a Cerevel acquisition assetAbbVie has secured FDA approval for tavapadon, marketed as Juvmo, for the treatment of Parkinson’s disease in adults. The decision follows positive results from the Phase 3 TEMPO trial. In the piv…